Photoactivated full-API nanodrug (FAND): harnessing transition metal complexes and MTH1 inhibitor for enhanced DNA damage in cancer cells-Reference-Cited by-同舟云学术

Photoactivated full-API nanodrug (FAND): harnessing transition metal complexes and MTH1 inhibitor for enhanced DNA damage in cancer cells

Published:2024 Issue:12 Volume:12 Page:3154-3162
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Zhu Huiyun¹,Cui Maozhi¹,Tang Qiang¹^ORCID,Zhao Hua¹,Zhang Pu¹^ORCID,Zeng Shengmei¹,Li Weiyu²,Zhou Qianxiong³^ORCID,Zhang Jinfeng²^ORCID,Chen Yongjie¹

Affiliation:

1. Research Center for Pharmacodynamic Evaluation Engineering Technology of Chongqing, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China

2. School of Life Science, Beijing Institute of Technology, Beijing 100081, China

3. Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China

Abstract

The photoactivated nanodrug Ru–T FAND by self-assembly of RuDPB and TH287 was developed to achieve triple anti-cancer therapy.

Funder

National Natural Science Foundation of China

Science and Technology Planning Project of Yuzhong District of Chongqing City

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/BM/D4BM00316K

Reference38 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer statistics, 2023

3. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application

4. Recent advances in noble metal complex based photodynamic therapy

5. An open source and reduce expenditure ROS generation strategy for chemodynamic/photodynamic synergistic therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quintuple Free‐Radical Therapy: An Ultralong‐Retention FAND for NIR‐Involved Multiple Site‐Acting Hypoxic Tumor Therapy;Advanced Functional Materials;2024-07